User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.

Primary tabs

Arts, Florence [UCL] Chand, D Pecquet, Christian [UCL] Velghe, Amélie [UCL] Constantinescu, Stefan N. [UCL] Demoulin, Jean-Baptiste [UCL]

Recently, germline and somatic heterozygous mutations in the platelet-derived growth factor receptor β (PDGFRB) have been associated with familial infantile myofibromatosis (IM), which is characterized by soft tissue tumors, and overgrowth syndrome, a disease that predisposes to cancer. These mutations have not been functionally characterized. In the present study, the activity of three PDGFRB mutants associated with familial IM (R561C, P660T and N666K) and one PDGFRB mutant found in patients with overgrowth syndrome (P584R) was tested in various models. The P660T mutant showed no difference with the wild-type receptor, suggesting that it might represent a polymorphic variant unrelated to the disease. By contrast, the three other mutants were constitutively active and able to transform NIH3T3 and Ba/F3 cells to different extents. In particular, the germline mutant identified in overgrowth syndrome, P584R, was a stronger oncogene than the germline R561C mutant associated with myofibromatosis. The distinct phenotypes associated with these two mutations could be related to this difference of potency. Importantly, all activated mutants were sensitive to tyrosine kinase inhibitors such as imatinib, nilotinib and ponatinib. In conclusion, the PDGFRB mutations previously identified in familial IM and overgrowth syndrome activate the receptor in the absence of ligand, supporting the hypothesis that these mutations cause the diseases. Moreover, imatinib seems to be a promising treatment for patients carrying these mutations. To our knowledge, these are the first confirmed gain-of-function point mutations of PDGFRB in human cancer.Oncogene advance online publication, 12 October 2015; doi:10.1038/onc.2015.383.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2015
Language Anglais
Journal information "Oncogene : including Oncogene Reviews" - Vol. 35, no. 25, p. 3239-48 (2016)
Peer reviewed yes
Publisher Nature Publishing Group (London)
issn 0950-9232
e-issn 1476-5594
Publication status Publié
Affiliation UCL - SSS/DDUV - Institut de Duve
Links
  1. Zand Dina J., Huff Dale, Everman David, Russell Karen, Saitta Sulagna, McDonald-McGinn Donna, Zackai Elaine H., Autosomal dominant inheritance of infantile myofibromatosis, 10.1002/ajmg.a.20598
  2. Mashiah Jacob, Hadj-Rabia Smail, Dompmartin Anne, Harroche Annie, Laloum-Grynberg Etty, Wolter Michèle, Amoric Jean-Claude, Hamel-Teillac Dominique, Guero Stéphane, Fraitag Sylvie, Bodemer Christine, Infantile myofibromatosis: A series of 28 cases, 10.1016/j.jaad.2014.03.035
  3. Wiswell TE, Pediatrics, 76, 981 (1985)
  4. Miklossy Judit, Mackenzie Ian R., Dorovini-Zis Katerina, Calne Donald B., Wszolek Zbigniew K., Klegeris Andis, McGeer Patrick L., Severe vascular disturbance in a case of familial brain calcinosis, 10.1007/s00401-005-1007-7
  5. Ang P, Cutis, 73, 229 (2004)
  6. Chung E. B., Enzinger Franz M., Infantile myofibromatosis, 10.1002/1097-0142(19811015)48:8<1807::aid-cncr2820480818>3.0.co;2-g
  7. Bračko Matej, Cindro Lada, Golouh Rastko, Familial occurrence of infantile myofibromatosis, 10.1002/cncr.2820690537
  8. Martignetti John A., Tian Lifeng, Li Dong, Ramirez Maria Celeste M., Camacho-Vanegas Olga, Camacho Sandra Catalina, Guo Yiran, Zand Dina J., Bernstein Audrey M., Masur Sandra K., Kim Cecilia E., Otieno Frederick G., Hou Cuiping, Abdel-Magid Nada, Tweddale Ben, Metry Denise, Fournet Jean-Christophe, Papp Eniko, McPherson Elizabeth W., Zabel Carrie, Vaksmann Guy, Morisot Cyril, Keating Brendan, Sleiman Patrick M., Cleveland Jeffrey A., Everman David B., Zackai Elaine, Hakonarson Hakon, Mutations in PDGFRB Cause Autosomal-Dominant Infantile Myofibromatosis, 10.1016/j.ajhg.2013.04.024
  9. Cheung Yee Him, Gayden Tenzin, Campeau Philippe M., LeDuc Charles A., Russo Donna, Nguyen Van-Hung, Guo Jiancheng, Qi Ming, Guan Yanfang, Albrecht Steffen, Moroz Brenda, Eldin Karen W., Lu James T., Schwartzentruber Jeremy, Malkin David, Berghuis Albert M., Emil Sherif, Gibbs Richard A., Burk David L., Vanstone Megan, Lee Brendan H., Orchard David, Boycott Kym M., Chung Wendy K., Jabado Nada, A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis, 10.1016/j.ajhg.2013.04.026
  10. Demoulin Jean-Baptiste, Essaghir Ahmed, PDGF receptor signaling networks in normal and cancer cells, 10.1016/j.cytogfr.2014.03.003
  11. Andrae J., Gallini R., Betsholtz C., Role of platelet-derived growth factors in physiology and medicine, 10.1101/gad.1653708
  12. Soriano P, Development, 124, 2691 (1997)
  13. Soriano P, Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice., 10.1101/gad.8.16.1888
  14. Verstraete Kenneth, Savvides Savvas N., Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases, 10.1038/nrc3371
  15. Chiara Federica, Bishayee Subal, Heldin Carl-Henrik, Demoulin Jean-Baptiste, Autoinhibition of the Platelet-derived Growth Factor β-Receptor Tyrosine Kinase by Its C-terminal Tail, 10.1074/jbc.m314070200
  16. Toffalini F., Demoulin J.-B., New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases, 10.1182/blood-2010-04-279752
  17. Heldin Carl-Henrik, Östman Arne, Rönnstrand Lars, Signal transduction via platelet-derived growth factor receptors, 10.1016/s0304-419x(98)00015-8
  18. Lacerda Lda S, Radiol Res Pract, 2014, 947451 (2014)
  19. Takenouchi Toshiki, Yamaguchi Yu, Tanikawa Akiko, Kosaki Rika, Okano Hideyuki, Kosaki Kenjiro, Novel Overgrowth Syndrome Phenotype Due to Recurrent De Novo PDGFRB Mutation, 10.1016/j.jpeds.2014.10.015
  20. Heldin Carl-Henrik, Targeting the PDGF signaling pathway in tumor treatment, 10.1186/1478-811x-11-97
  21. Chiara Federica, Goumans Marie-José, Forsberg Henrik, Ahgrén Aive, Rasola Andrea, Aspenström Pontus, Wernstedt Christer, Hellberg Carina, Heldin Carl-Henrik, Heuchel Rainer, A Gain of Function Mutation in the Activation Loop of Plateletderived Growth Factor β-Receptor Deregulates Its Kinase Activity, 10.1074/jbc.m406051200
  22. Medves S, Duhoux F P, Ferrant A, Toffalini F, Ameye G, Libouton J-M, Poirel H A, Demoulin J-B, KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia, 10.1038/leu.2010.13
  23. Cools Jan, DeAngelo Daniel J., Gotlib Jason, Stover Elizabeth H., Legare Robert D., Cortes Jorges, Kutok Jeffrey, Clark Jennifer, Galinsky Ilene, Griffin James D., Cross Nicholas C.P., Tefferi Ayalew, Malone James, Alam Rafeul, Schrier Stanley L., Schmid Janet, Rose Michal, Vandenberghe Peter, Verhoef Gregor, Boogaerts Marc, Wlodarska Iwona, Kantarjian Hagop, Marynen Peter, Coutre Steven E., Stone Richard, Gilliland D. Gary, A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome, 10.1056/nejmoa025217
  24. Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., Hannequin D., Campion D., Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification, 10.1212/wnl.0b013e31827ccf34
  25. Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., Campion D., Hannequin D., Ahtoy P., Anheim M., Augustin J., Ayrignac X., Bille-Turc F., Campion D., Chaumette B., Clanet M., Defebvre L., Defer G., Derache N., Didic M., Durif F., Flamand-Roze E., Fromager G., Giroud M., Goldenberg A., Guillin O., Guyant-Marechal L., Hannequin D., Hubsch C., Jurici S., Krystkowiak P., Labauge P., Layet A., Le Ber I., Lebouvier T., Lefaucheur R., Maltete D., Morcamp O. M. D., Nicolas G., Ozkul O., Pariente J., Pottier C., Rondepierre P., Rouaud O., Salle B., Sauvee M., Schaeffer S., Thauvin-Robinet C., Thomas-Anterion C., Tranchant C., Triquenot A., Vaschalde Y., Verin M., Verny C., Vidailhet M., Wallon D., , Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification, 10.1093/brain/awt255
  26. Arts Florence A., Velghe Amélie I., Stevens Monique, Renauld Jean-Christophe, Essaghir Ahmed, Demoulin Jean-Baptiste, Idiopathic basal ganglia calcification-associatedPDGFRBmutations impair the receptor signalling, 10.1111/jcmm.12443
  27. Schönherr Christina, Ruuth Kristina, Yamazaki Yasuo, Eriksson Therese, Christensen James, Palmer Ruth H., Hallberg Bengt, Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684, 10.1042/bj20101796
  28. NAKAHARA M, ISOZAKI K, HIROTA S, MIYAGAWA J, HASESAWADA N, TANIGUCHI M, NISHIDA T, KANAYAMA S, KITAMURA Y, SHINOMURA Y, A novel gain-of-function mutation of c- gene in gastrointestinal stromal tumors, 10.1016/s0016-5085(98)70079-4
  29. Heinrich M. C., PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors, 10.1126/science.1079666
  30. Looman Camilla, Sun Tong, Yu Yang, Zieba Agata, Ahgren Aive, Feinstein Ricardo, Forsberg Henrik, Hellberg Carina, Heldin Carl-Henrik, Zhang Xiao-Qun, Forsberg-Nilsson Karin, Khoo Nelson, Fundele Reinald, Heuchel Rainer, An activating mutation in the PDGF receptor-beta causes abnormal morphology in the mouse placenta, 10.1387/ijdb.072301cl
  31. Keating MT, J Biol Chem, 264, 9129 (1989)
  32. Demoulin JB, Cancer Res, 60, 3971 (2000)
  33. Velghe A I, Van Cauwenberghe S, Polyansky A A, Chand D, Montano-Almendras C P, Charni S, Hallberg B, Essaghir A, Demoulin J-B, PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations, 10.1038/onc.2013.218
  34. Corless Christopher L., Schroeder Arin, Griffith Diana, Town Ajia, McGreevey Laura, Harrell Patina, Shiraga Sharon, Bainbridge Troy, Morich Jason, Heinrich Michael C., PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib, 10.1200/jco.2005.14.068
  35. David M., Cross N. C. P., Burgstaller S., Chase A., Curtis C., Dang R., Gardembas M., Goldman J. M., Grand F., Hughes G., Huguet F., Lavender L., McArthur G. A., Mahon F. X., Massimini G., Melo J., Rousselot P., Russell-Jones R. J., Seymour J. F., Smith G., Stark A., Waghorn K., Nikolova Z., Apperley J. F., Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders, 10.1182/blood-2006-05-024828
  36. Li-Wan-Po Alain, Farndon Peter, Craddock Charles, Griffiths Michael, Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example, 10.1007/s00228-009-0779-4
  37. Linhares N.D., Freire M.C.M., Cardenas R.G.C.C.L., Bahia M., Puzenat E., Aubin F., Pena S.D.J., Short Communication Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?, 10.4238/2014.august.15.11
  38. Barker Karen T, Houlston Richard S, Overgrowth syndromes: is dysfunctional PI3-kinase signalling a unifying mechanism?, 10.1038/sj.ejhg.5201026
  39. Lindhurst Marjorie J., Sapp Julie C., Teer Jamie K., Johnston Jennifer J., Finn Erin M., Peters Kathryn, Turner Joyce, Cannons Jennifer L., Bick David, Blakemore Laurel, Blumhorst Catherine, Brockmann Knut, Calder Peter, Cherman Natasha, Deardorff Matthew A., Everman David B., Golas Gretchen, Greenstein Robert M., Kato B. Maya, Keppler-Noreuil Kim M., Kuznetsov Sergei A., Miyamoto Richard T., Newman Kurt, Ng David, O'Brien Kevin, Rothenberg Steven, Schwartzentruber Douglas J., Singhal Virender, Tirabosco Roberto, Upton Joseph, Wientroub Shlomo, Zackai Elaine H., Hoag Kimberly, Whitewood-Neal Tracey, Robey Pamela G., Schwartzberg Pamela L., Darling Thomas N., Tosi Laura L., Mullikin James C., Biesecker Leslie G., A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome, 10.1056/nejmoa1104017
  40. Millot Frédéric, Guilhot Joelle, Baruchel André, Petit Arnaud, Leblanc Thierry, Bertrand Yves, Mazingue Françoise, Lutz Patrick, Vérité Cecile, Berthou Christian, Galambrun Claire, Sirvent Nicolas, Yacouben Karima, Chastagner Pascal, Gandemer Virginie, Reguerre Yves, Couillault Gérard, Khalifeh Tackwa, Rialland Fanny, Growth deceleration in children treated with imatinib for chronic myeloid leukaemia, 10.1016/j.ejca.2014.10.007
  41. Demoulin Jean-Baptiste, Louahed Jamila, Dumoutier Laure, Stevens Monique, Renauld Jean-Christophe, MAP kinase activation by interleukin-9 in lymphoid and mast cell lines, 10.1038/sj.onc.1206253
  42. Noël Laura A., Arts Florence A., Montano-Almendras Carmen P., Cox Luk, Gielen Olga, Toffalini Federica, Marbehant Catherine Y., Cools Jan, Demoulin Jean-Baptiste, The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V, 10.1016/j.molonc.2014.02.003
  43. Medves S., Noel L. A., Montano-Almendras C. P., Albu R. I., Schoemans H., Constantinescu S. N., Demoulin J.-B., Multiple oligomerization domains of KANK1-PDGFR  are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK, 10.3324/haematol.2011.040147
Bibliographic reference Arts, Florence ; Chand, D ; Pecquet, Christian ; Velghe, Amélie ; Constantinescu, Stefan N. ; et. al. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.. In: Oncogene : including Oncogene Reviews, Vol. 35, no. 25, p. 3239-48 (2016)
Permanent URL http://hdl.handle.net/2078.1/167983